Avadel Pharmaceuticals Plc Stock Alpha and Beta Analysis
| AVDL Stock | USD 7.69 0.03 0.39% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Avadel Pharmaceuticals PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Avadel Pharmaceuticals over a specified time horizon. Remember, high Avadel Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Avadel Pharmaceuticals' market risk premium analysis include:
Beta 1.34 | Alpha (0.76) | Risk 5.29 | Sharpe Ratio (0.18) | Expected Return (0.96) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Avadel |
Avadel Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Avadel Pharmaceuticals market risk premium is the additional return an investor will receive from holding Avadel Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Avadel Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Avadel Pharmaceuticals' performance over market.| α | -0.76 | β | 1.34 |
Avadel Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Avadel Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Avadel Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Avadel Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Avadel Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Avadel Pharmaceuticals shares will generate the highest return on investment. By understating and applying Avadel Pharmaceuticals stock market price indicators, traders can identify Avadel Pharmaceuticals position entry and exit signals to maximize returns.
Avadel Pharmaceuticals Return and Market Media
The median price of Avadel Pharmaceuticals for the period between Fri, Nov 1, 2024 and Thu, Jan 30, 2025 is 10.72 with a coefficient of variation of 20.57. The daily time series for the period is distributed with a sample standard deviation of 2.25, arithmetic mean of 10.96, and mean deviation of 1.66. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | GENDELL JEFFREY Ls Strategic Acquisition of Friedman Industries Shares | 11/13/2024 |
2 | Acquisition by Palczuk Linda of 3000 shares of Avadel Pharmaceuticals at 10.1892 subject to Rule 16b-3 | 12/06/2024 |
3 | Acquisition by Gregory Divis of 402 shares of Avadel Pharmaceuticals at 9.82 subject to Rule 16b-3 | 12/09/2024 |
4 | Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy | 12/11/2024 |
5 | Disposition of 3500 shares by Palczuk Linda of Avadel Pharmaceuticals subject to Rule 16b-3 | 12/24/2024 |
6 | Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 | 01/03/2025 |
7 | Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635 | 01/06/2025 |
8 | Avadel Pharmaceuticals PLC Q4 2024 Earnings Report Preview What To Expect | 01/07/2025 |
9 | Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch | 01/08/2025 |
10 | Is Avadel Pharmaceuticals Using Debt In A Risky Way | 01/13/2025 |
11 | Insider Buying Peter Thornton Acquires 10,000 Shares of Avadel Pharmaceuticals PLC | 01/15/2025 |
12 | Acquisition by Palczuk Linda of 5000 shares of Avadel Pharmaceuticals at 7.928 subject to Rule 16b-3 | 01/21/2025 |
13 | Disposition of 25000 shares by Palczuk Linda of Avadel Pharmaceuticals at 10.93 subject to Rule 16b-3 | 01/24/2025 |
About Avadel Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Avadel or other stocks. Alpha measures the amount that position in Avadel Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.0666 | 0.0633 | Days Of Inventory On Hand | 4.0K | 4.2K |
Avadel Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Avadel Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avadel Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Avadel Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Avadel Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Avadel Pharmaceuticals' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Avadel Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Avadel Pharmaceuticals Backtesting, Avadel Pharmaceuticals Valuation, Avadel Pharmaceuticals Correlation, Avadel Pharmaceuticals Hype Analysis, Avadel Pharmaceuticals Volatility, Avadel Pharmaceuticals History and analyze Avadel Pharmaceuticals Performance. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Avadel Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.